Glaxo Smith Kline Phrmcuticals Revenue and Competitors
Estimated Revenue & Valuation
- Glaxo Smith Kline Phrmcuticals's estimated annual revenue is currently $126M per year.
- Glaxo Smith Kline Phrmcuticals's estimated revenue per employee is $201,000
Employee Data
- Glaxo Smith Kline Phrmcuticals has 627 Employees.
Glaxo Smith Kline Phrmcuticals's People
Name | Title | Email/Phone |
---|
Glaxo Smith Kline Phrmcuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $43.2M | 215 | 6% | N/A | N/A |
#2 | $81.8M | 407 | 10% | N/A | N/A |
#3 | $11.7M | 58 | 0% | N/A | N/A |
#4 | $1011.8M | 5034 | -9% | N/A | N/A |
#5 | $44.8M | 223 | 1% | N/A | N/A |
#6 | $13.1M | 65 | 5% | N/A | N/A |
#7 | $16.5M | 82 | 41% | N/A | N/A |
#8 | $17.3M | 86 | -5% | N/A | N/A |
#9 | $67.9M | 338 | 23% | N/A | N/A |
#10 | $14.9M | 74 | 7% | N/A | N/A |
What Is Glaxo Smith Kline Phrmcuticals?
Glaxo Smith Kline Phrmcuticals is a Pharmaceuticals company located in 122 Williams Ln, Feasterville Trevose, Pennsylvania, United States.
keywords:N/AN/A
Total Funding
627
Number of Employees
$126M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Glaxo Smith Kline Phrmcuticals News
2022-04-19 - GSK soars on Shingrix, COVID antibody
Ever since the pandemic started holding back GlaxoSmithKline's Shingrix, the company has repeatedly said its flagship shingles vaccine will...
2022-04-19 - GSK delivers strong Q1 2022 sales of £9.8 billion, +32% AER ...
GSK one of the world's leading research-based pharmaceutical and healthcare companies is committed to improving the quality of human...
2022-04-13 - GlaxoSmithKline manufacturing staffers in UK vote to strike ...
Hundreds of GSK employees in the U.K. have voted to strike against a derisory pay raise offer from the British Big Pharma, local labor union Unite said in...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $216.1M | 735 | -5% | N/A |
#2 | $75M | 898 | N/A | N/A |
#3 | $35M | 1110 | N/A | N/A |
#4 | $283M | 1394 | 16% | N/A |
#5 | $300M | 1578 | N/A | N/A |